Distinct Features of Vascular Diseases in COVID-19

References

• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi:10.1001/jama.2020.1585
   PubMed Web of Science ®Google Scholar
• Xu YH, Dong JH, An WM, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect. 2020;80:394–400. doi:10.1016/j.jinf.2020.02.017
   PubMed Web of Science ®Google Scholar
• Ulinici M, Covantev S, Wingfield-Digby J, et al. Screening, diagnostic and prognostic tests for COVID-19: a comprehensive review. Life. 2021;11:561. doi:10.3390/life11060561
   PubMedGoogle Scholar
• Saber-Ayad M, Saleh MA, Abu-Gharbieh E. The rationale for potential pharmacotherapy of COVID-19. Pharmaceuticals. 2020;13:96. doi:10.3390/ph13050096
   Web of Science ®Google Scholar
• Bonnesen B, Jensen JUS, Jeschke KN, et al. Management of COVID-19-associated acute respiratory failure with alternatives to invasive mechanical ventilation: high-flow oxygen, continuous positive airway pressure, and noninvasive ventilation. Diagnostics. 2021;11:2259. doi:10.3390/diagnostics11122259
   Web of Science ®Google Scholar
• Stoichitoiu LE, Pinte L, Ceasovschih A, et al. In-hospital antibiotic use for COVID-19: facts and rationales assessed through a mixed-methods study. J Clin Med. 2022;11(11):3194. doi:10.3390/jcm11113194
   PubMed Web of Science ®Google Scholar
• Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17(5):259–260. doi:10.1038/s41569-020-0360-5
   PubMed Web of Science ®Google Scholar
• Leung TYM, Chan AYL, Chan EW, et al. Short- and potential long-term adverse health outcomes of Covid-19: a rapid review. Emerg Microbes Infect. 2020;9:2190–2199. doi:10.1080/22221751.2020.1825914
   PubMed Web of Science ®Google Scholar
• Monteil V, Kwon H, Prado P. Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. Cell. 2020;181(4):905–913. doi:10.1016/j.cell.2020.04.004
   PubMed Web of Science ®Google Scholar
• Hohberger B, Ganslmayer M, Lucio M, et al. Retinal microcirculation as a correlate of a systemic capillary impairment after severe acute respiratory syndrome coronavirus 2 infection. Front Med. 2021;8:676554. doi:10.3389/fmed.2021.676554
   Web of Science ®Google Scholar
• Osiaevi I, Schulze A, Evers G, et al. Persistent capillary rarefication in long COVID syndrome. Angiogenesis. 2023;26(1):53–61. doi:10.1007/s10456-022-09850-9
   PubMed Web of Science ®Google Scholar
• Gavriilaki E, Anyfanti P, Gavriilaki M, et al. Endothelial dysfunction in COVID-19: lessons learned from coronaviruses. Curr Hypertens Rep. 2020;22(9):63. doi:10.1007/s11906-020-01078-6
   PubMed Web of Science ®Google Scholar
• Nakano H, Shiina K, Tomiyama H. Cardiovascular outcomes in the acute phase of COVID-19. Int J Mol Sci. 2021;22(8):4071. doi:10.3390/ijms22084071
   PubMed Web of Science ®Google Scholar
• Vlacil AK, Bänfer S, Jacob R, et al. Polystyrene microplastic particles induce endothelial activation. PLoS One. 2021;16(11):e0260181. doi:10.1371/journal.pone.0260181
   PubMed Web of Science ®Google Scholar
• Endemann DH, Schiffrin EL. Endothelial Dysfunction. J Am Soc Nephrol. 2004;15(8):1983–1992. doi:10.1097/01.ASN.0000132474.50966.DA
   PubMed Web of Science ®Google Scholar
• Kotlyarov S, Kotlyarova A. The importance of the plasma membrane in atherogenesis. Membranes. 2022;12:1036. doi:10.3390/membranes12111036
   PubMed Web of Science ®Google Scholar
• Tripska K, Igreja Sá IC, Vasinova M, et al. Monoclonal anti-endoglin antibody TRC105 (carotuximab) prevents hypercholesterolemia and hyperglycemia-induced endothelial dysfunction in human aortic endothelial cells. Front Med. 2022;9:845918. doi:10.3389/fmed.2022.845918
   Web of Science ®Google Scholar
• Alexander Y, Osto E, Schmidt-Trucksäss A, et al. Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on atherosclerosis and vascular biology, aorta and peripheral vascular diseases, coronary pathophysiology and microcirculation, and thrombosis. Cardiovasc Res. 2020;117(1):29–42.
   Web of Science ®Google Scholar
• Kotlyarov S. Analysis of differentially expressed genes and signaling pathways involved in atherosclerosis and chronic obstructive pulmonary disease. Biomol Concepts. 2022;13(1):34–54. doi:10.1515/bmc-2022-0001
   PubMedGoogle Scholar
• Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120–128. doi:10.1056/NEJMoa2015432
   PubMed Web of Science ®Google Scholar
• Amraei R, Rahimi N. COVID-19, renin-angiotensin system and endothelial dysfunction. Cells. 2020;9(7):1652. doi:10.3390/cells9071652
   PubMed Web of Science ®Google Scholar
• Shankar A, Varadan B, Ethiraj D, et al. Systemic arterio-venous thrombosis in COVID-19: a pictorial review. World J Radiol. 2021;13(1):19–28. doi:10.4329/wjr.v13.i1.19
   PubMed Web of Science ®Google Scholar
• Sanders MJ, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824–1836. doi:10.1001/jama.2020.6019
   PubMed Web of Science ®Google Scholar
• South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318:1084–1090. doi:10.1152/ajpheart.00217.2020
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. doi:10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Khomich OA, Kochetkov SN, Bartosch B, Barr JJ, Bollyky PL. Redox biology of respiratory viral infections. Viruses. 2018;11:10. doi:10.3390/v11010010
   PubMedGoogle Scholar
• Bhaskar S, Sinha A, Banach M, et al. Cytokine storm in COVID-19-immunopathological mechanisms, clinical considerations, and therapeutic approaches: the REPROGRAM consortium position paper. Front Immunol. 2020;10(11):1648. doi:10.3389/fimmu.2020.01648
   Google Scholar
• Coman AE, Ceasovschih A, Petroaie AD, et al. The significance of low magnesium levels in COVID-19 patients. Medicina. 2023;59(2):279. doi:10.3390/medicina59020279
   PubMedGoogle Scholar
• Jin Y, Ji W, Yang H, et al. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020;5(1):293. doi:10.1038/s41392-020-00454-7
   PubMed Web of Science ®Google Scholar
• Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 2020;18(7):1738–1742. doi:10.1111/jth.14850
   PubMed Web of Science ®Google Scholar
• Rovas A, Osiaevi I, Buscher K, et al. Microvascular dysfunction in COVID-19: the MYSTIC study. Angiogenesis. 2021;24(1):145–157. doi:10.1007/s10456-020-09753-7
   PubMed Web of Science ®Google Scholar
• Queisser KA, Mellema RA, Middleton EA, et al. COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight. 2021;6(17):e147472. doi:10.1172/jci.insight.147472
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P. Arterial stiffness and hypertension in the elderly. Front Cardiovasc Med. 2020;7. doi:10.3389/fcvm.2020.544302
   PubMed Web of Science ®Google Scholar
• Donato AJ, Machin DR, Lesniewski LA. Mechanisms of dysfunction in the aging vasculature and role in age-related disease. Circ Res. 2018;123:825–848. doi:10.1161/CIRCRESAHA.118.312563
   PubMed Web of Science ®Google Scholar
• Lacolley P, Regnault V, Laurent S. Mechanisms of arterial stiffening: from mechanotransduction to epigenetics. Arterioscler Thromb Vasc Biol. 2020;40:1055–1062. doi:10.1161/ATVBAHA.119.313129
   PubMed Web of Science ®Google Scholar
• Lyle AN, Raaz U. Killing me unsoftly: causes and mechanisms of arterial stiffness. Arterioscler Thromb Vasc Biol. 2017;37:1–11. doi:10.1161/ATVBAHA.116.308563
   PubMed Web of Science ®Google Scholar
• Tsioufis C, Dimitriadis K. Sympathetic system-related artery stiffness. Hypertension. 2019;73(5):975–976. doi:10.1161/HYPERTENSIONAHA.119.12571
   PubMed Web of Science ®Google Scholar
• Zota IM, Stătescu C, Sascău RA, et al. Arterial stiffness assessment using the arteriograph in patients with moderate–severe OSA and metabolic syndrome—a pilot study. J Clin Med. 2021;10:4238.
   PubMed Web of Science ®Google Scholar
• Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37:1236–1241.
   PubMed Web of Science ®Google Scholar
• Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation. 2010;121:505–511. doi:10.1161/CIRCULATIONAHA.109.886655
   PubMed Web of Science ®Google Scholar
• Niiranen TJ, Kalesan B, Hamburg NM, et al. Relative contributions of arterial stiffness and hypertension to cardiovascular disease: the Framingham Heart Study. J Am Heart Assoc. 2016;5. doi:10.1161/JAHA.116.004271
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55:1318–1327. doi:10.1016/j.jacc.2009.10.061
   PubMed Web of Science ®Google Scholar
• Wang XK, Keith JC, Struthers AD, et al. Assessment of arterial stiffness, a translational medicine biomarker system for evaluation of vascular risk. Cardiovasc Ther. 2008;26:214–223. doi:10.1111/j.1755-5922.2008.00051.x
   PubMed Web of Science ®Google Scholar
• Zota IM, Stătescu C, Sascău RA, et al. Acute and long-term consequences of COVID-19 on arterial stiffness—a narrative review. Life. 2022;12:781. doi:10.3390/life12060781
   PubMedGoogle Scholar
• Schnaubelt S, Oppenauer J, Tihanyi D, et al. Arterial stiffness in acute COVID-19 and potential associations with clinical outcome. J Intern Med. 2021;290:437–443. doi:10.1111/joim.13275
   PubMed Web of Science ®Google Scholar
• Ratchford SM, Stickford JL, Province VM, et al. Vascular alterations among young adults with SARS-CoV-2. Am J Physiol. 2021;320:404–410.
   PubMed Web of Science ®Google Scholar
• Szeghy RE, Province VM, Stute NL, et al. Carotid stiffness, intima-media thickness and aortic augmentation index among adults with SARS-CoV-2. Exp Physiol. 2022;107:694–707. doi:10.1113/EP089481
   PubMed Web of Science ®Google Scholar
• Kumar N, Kumar S, Kumar A, et al. The COSEVAST study outcome: evidence of COVID-19 severity proportionate to surge in arterial stiffness. Indian J Crit Care Med. 2021;25:1113–1119. doi:10.5005/jp-journals-10071-24000
   PubMed Web of Science ®Google Scholar
• Nandadeva D, Young BE, Stephens BY, et al. Blunted peripheral but not cerebral vasodilator function in young otherwise healthy adults with persistent symptoms following COVID-19. Am J Physiol. 2021;321:479–484.
   PubMed Web of Science ®Google Scholar
• Szeghy RE, Stute NL, Province VM, et al. Six-month longitudinal tracking of arterial stiffness and blood pressure in young adults following SARS-CoV-2 infection. J Appl Physiol. 2022;132:1297–1309. doi:10.1152/japplphysiol.00793.2021
   PubMed Web of Science ®Google Scholar
• Spronck B, Heusinkveld MH, Vanmolkot FH, et al. Pressure-dependence of arterial stiffness: potential clinical implications. J Hypertens. 2015;33:330–338. doi:10.1097/HJH.0000000000000407
   PubMed Web of Science ®Google Scholar
• Nandadeva D, Skow RJ, Grotle AK, et al. Impact of COVID-19 on ambulatory blood pressure in young adults: a cross-sectional analysis investigating time since diagnosis. J Appl Physiol. 2022;133:183–190. doi:10.1152/japplphysiol.00216.2022
   PubMed Web of Science ®Google Scholar
• Küçük U, Gazi E, Duygu A, et al. Evaluation of aortic elasticity parameters in survivors of COVID-19 using echocardiography imaging. Med Princ Pract. 2022;31:276–283. doi:10.1159/000522626
   PubMed Web of Science ®Google Scholar
• Zanoli L, Gaudio A, Mikhailidis DP, et al. Vascular dysfunction of COVID-19 is partially reverted in the long-term. Circ Res. 2022;130:1276–1285. doi:10.1161/CIRCRESAHA.121.320460
   PubMed Web of Science ®Google Scholar
• Lambadiari V, Mitrakou A, Kountouri A, et al. Association of COVID-19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection. Eur J Heart Fail. 2021;23:1916–1926. doi:10.1002/ejhf.2326
   PubMed Web of Science ®Google Scholar
• Ikonomidis I, Lambadiari V, Mitrakou A, et al. Myocardial work and vascular dysfunction are partially improved at 12 months after COVID-19 infection. Eur J Heart Fail. 2022;24:727–729. doi:10.1002/ejhf.2451
   PubMed Web of Science ®Google Scholar
• Van der Sluijs KM, Bakker EA, Schuijt TJ, et al. Long-term cardiovascular health status and physical functioning of nonhospitalized patients with COVID-19 compared with non-COVID-19 controls. Am J Physiol Heart Circ Physiol. 2023;324:47–56.
   Web of Science ®Google Scholar
• Abers MS, Delmonte OM, Ricotta EE, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight. 2021;2021:6.
   Google Scholar
• Gelzo M, Cacciapuoti S, Pinchera B, et al. Matrix metalloproteinases (MMP) 3 and 9 as biomarkers of severity in COVID-19 patients. Sci Rep. 2022;12:1212. doi:10.1038/s41598-021-04677-8
   PubMed Web of Science ®Google Scholar
• Ueland T, Holter JC, Holten AR, et al. Distinct and early increase in circulating MMP-9 in COVID-19 patients with respiratory failure. J Infect. 2020;81:41–43. doi:10.1016/j.jinf.2020.06.061
   PubMed Web of Science ®Google Scholar
• Lerum TV, Maltzahn NN, Aukrust P, et al. Persistent pulmonary pathology after COVID-19 is associated with high viral load, weak antibody response, and high levels of matrix metalloproteinase-9. Sci Rep. 2021;11:23205. doi:10.1038/s41598-021-02547-x
   PubMed Web of Science ®Google Scholar
• Shi S, Su M, Shen G, et al. Matrix metalloproteinase 3 as a valuable marker for patients with COVID-19. J Med Virol. 2021;93:528–532. doi:10.1002/jmv.26235
   PubMed Web of Science ®Google Scholar
• Springall R, Gonzalez-Florez J, Garcia-Avila C, et al. Elevated levels of soluble CD147 are associated with hyperinflammation and disease severity in COVID-19: a proof-of-concept clinical study. Arch Immunol Ther Exp (Warsz). 2022;70:18. doi:10.1007/s00005-022-00657-6
   PubMed Web of Science ®Google Scholar
• Wang M, Kim SH, Monticone RE, et al. Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosis. Hypertension. 2015;65:698–703. doi:10.1161/HYPERTENSIONAHA.114.03618
   PubMed Web of Science ®Google Scholar
• Bruno RM, Spronck B, Hametner B, et al. Covid-19 effects on arterial stiffness and vascular ageing: CARTESIAN study rationale and protocol. Artery Res. 2020;27:59. doi:10.2991/artres.k.201124.001
   PubMed Web of Science ®Google Scholar
• Esobi I, Lasode M, Anyanwu C, et al. Nutritional impact of COVID-19 and its implications on atherosclerosis. World. 2020;8(1):16–21.
   Google Scholar
• Kotlyarov S. Diversity of lipid function in atherogenesis: a focus on endothelial mechanobiology. Int J Mol Sci. 2021;22:11545. doi:10.3390/ijms222111545
   PubMed Web of Science ®Google Scholar
• Vinciguerra M, Romiti S, Fattouch K, et al. Atherosclerosis as pathogenetic substrate for Sars-Cov2 cytokine storm. J Clin Med. 2020;9:2095. doi:10.3390/jcm9072095
   PubMed Web of Science ®Google Scholar
• Kotlyarov S. Immune function of endothelial cells: evolutionary aspects, molecular biology and role in atherogenesis. Int J Mol Sci. 2022;23:9770. doi:10.3390/ijms23179770
   PubMed Web of Science ®Google Scholar
• Sukhorukov VN, Khotina VA, Chegodaev YS, Ivanova E, Sobenin IA, Orekhov AN. Lipid metabolism in macrophages: focus on atherosclerosis. Biomedicines. 2020;8(8):262. doi:10.3390/biomedicines8080262
   PubMed Web of Science ®Google Scholar
• Sagris M, Theofilis P, Antonopoulos AS, et al. Inflammatory mechanisms in COVID-19 and atherosclerosis: current pharmaceutical perspectives. Int J Mol Sci. 2021;22:6607. doi:10.3390/ijms22126607
   PubMed Web of Science ®Google Scholar
• Kotlyarov S, Kotlyarova A. Involvement of fatty acids and their metabolites in the development of inflammation in atherosclerosis. Int J Mol Sci. 2022;23:1308. doi:10.3390/ijms23031308
   PubMed Web of Science ®Google Scholar
• Grzegorowska O, Lorkowski J. Possible correlations between atherosclerosis, acute coronary syndromes and COVID-19. J Clin Med. 2020;9:3746. doi:10.3390/jcm9113746
   PubMed Web of Science ®Google Scholar
• Surma S, Banach M, Lewek J. COVID-19 and lipids. The role of lipid disorders and statin use in the prognosis of patients with SARS-CoV-2 infection. Lipids Health Dis. 2021;20(1):141. doi:10.1186/s12944-021-01563-0
   PubMed Web of Science ®Google Scholar
• Radenkovic D, Chawla S, Pirro M, et al. Cholesterol in relation to COVID-19: should we care about It? J Clin Med. 2020;9:1909. doi:10.3390/jcm9061909
   PubMed Web of Science ®Google Scholar
• Wang H, Yuan Z, Pavel MA, et al. Cholesterol and COVID19 lethality in elderly. bioRxiv. 2020;10:2020–2025.
   Google Scholar
• Luo W, Yu H, Gou J, et al. Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19). Preprints. 2020;2020:2020020407.
   Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538. doi:10.1007/s00392-020-01626-9
   PubMed Web of Science ®Google Scholar
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371. doi:10.1016/j.jacc.2020.03.031
   PubMed Web of Science ®Google Scholar
• Wang Q. Molecular genetics of coronary artery disease. Curr Opin Cardiol. 2005;20(3):182–188. doi:10.1097/01.hco.0000160373.77190.f1
   PubMed Web of Science ®Google Scholar
• Khera AV, Kathiresan S. Genetics of coronary artery disease: discovery, biology and clinical translation. Nat Rev Genet. 2017;18(6):331–344. doi:10.1038/nrg.2016.160
   PubMed Web of Science ®Google Scholar
• Aursulesei Onofrei V, Ceasovschih A, Anghel RC, et al. Subendocardial viability ratio predictive value for cardiovascular risk in hypertensive patients. Medicina. 2023;59(1):24. doi:10.3390/medicina59010024
   Google Scholar
• Zahmatkeshan N, Khademian Z, Zarshenas L, et al. Experience of adherence to treatment among patients with coronary artery disease during the COVID-19 pandemic: a qualitative study. Health Promot Perspect. 2021;11(4):467–475. doi:10.34172/hpp.2021.59
   PubMed Web of Science ®Google Scholar
• Anghel L, Tudurachi BS, Leonte A, et al. The challenge of high coronary thrombotic events in patients with ST-segment elevation myocardial infarction and COVID-19. J Clin Med. 2022;11:6542. doi:10.3390/jcm11216542
   PubMedGoogle Scholar
• Maehl N, Bleckwenn M, Riedel-Heller SG, et al. The impact of the COVID-19 pandemic on avoidance of health care, symptom severity, and mental well-being in patients with coronary artery disease. Front Med. 2021;8:760265. doi:10.3389/fmed.2021.760265
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID‐19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054‐1062. doi:10.1016/S0140-6736(20)30566-3
   Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720. doi:10.1056/NEJMoa2002032
   Web of Science ®Google Scholar
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. doi:10.1001/jamacardio.2020.0950
   PubMed Web of Science ®Google Scholar
• Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83–92. doi:10.1016/S1473-3099(09)70331-7
   PubMed Web of Science ®Google Scholar
• Timpau AS, Miftode RS, Leca D, et al. A real Pandora’s box in pandemic times: a narrative review on the acute cardiac injury due to COVID-19. Life. 2022;12:1085. doi:10.3390/life12071085
   PubMedGoogle Scholar
• Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040. doi:10.1182/blood.2020006000
   PubMed Web of Science ®Google Scholar
• De Michele S, Sun Y, Yilmaz MM. Forty postmortem examinations in COVID-19 patients. Am J Clin Pathol. 2020;154(6):748–760. doi:10.1093/ajcp/aqaa156
   PubMed Web of Science ®Google Scholar
• De Donato G, Pasqui E, Alba G, et al. The Limitations of social behaviour imposed by Covid-19 impacted the perception and the evolution of peripheral arterial disease negatively. Ann Vasc Surg. 2021;73:107–113. doi:10.1016/j.avsg.2021.02.003
   PubMed Web of Science ®Google Scholar
• Bermejo-Martin JF, Almansa R, Torres A, et al. Covid-19 as a cardiovascular disease: the potential role of chronic endothelial dysfunction. Cardiovasc Res. 2020;116:132–133. doi:10.1093/cvr/cvaa140
   PubMed Web of Science ®Google Scholar
• Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in Covid-19. Lancet. 2020;395:1417–1418. doi:10.1016/S0140-6736(20)30937-5
   PubMed Web of Science ®Google Scholar
• Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clin Exp Immunol. 2004;136(1):95–103. doi:10.1111/j.1365-2249.2004.02415.x
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687. doi:10.1093/cvr/cvaa106
   PubMed Web of Science ®Google Scholar
• Duca ȘT, Chetran A, Miftode RȘ, et al. Myocardial ischemia in patients with COVID-19 infection: between pathophysiological mechanisms and electrocardiographic findings. Life. 2022;12:1015. doi:10.3390/life12071015
   PubMedGoogle Scholar
• Yu CM, Wong RS, Wu EB, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–144. doi:10.1136/pgmj.2005.037515
   PubMed Web of Science ®Google Scholar
• Mahallawi WH, Khabour OF, Zhang Q, et al. MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile. Cytokine. 2018;104:8–13. doi:10.1016/j.cyto.2018.01.025
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe. 2016;19(2):181–193. doi:10.1016/j.chom.2016.01.007
   PubMed Web of Science ®Google Scholar
• Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. JAHA. 2014;3(2):000582. doi:10.1161/JAHA.113.000582
   Google Scholar
• Goeller M, Achenbach S, Marwan M, et al. Epicardial adipose tissue density and volume are related to subclinical atherosclerosis, inflammation and major adverse cardiac events in asymptomatic subjects. J Cardiovasc Comput Tomogr. 2018;12(1):67–73. doi:10.1016/j.jcct.2017.11.007
   PubMed Web of Science ®Google Scholar
• Mordi IR, Badar AA, Irving RJ, et al. Efficacy of noninvasive cardiac imaging tests in diagnosis and management of stable coronary artery disease. Vasc Health Risk Manag. 2017;13:427–437. doi:10.2147/VHRM.S106838
   PubMed Web of Science ®Google Scholar
• Araiza-Garaygordobil D, Montalto C, Martinez-Amezcua P, et al. Impact of the COVID-19 pandemic on hospitalizations for acute coronary syndromes: a multinational study. QJM. 2021;114(9):642–647. doi:10.1093/qjmed/hcab013
   PubMed Web of Science ®Google Scholar
• Kui L, Fang YY, Deng Y, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020;133(9):1025–1031. doi:10.1097/CM9.0000000000000744
   PubMed Web of Science ®Google Scholar
• Kermali M, Khalsa RK, Pillai K, et al. The role of biomarkers in diagnosis of COVID-19 – a systematic review. Life Sci. 2020;254:117788. doi:10.1016/j.lfs.2020.117788
   PubMed Web of Science ®Google Scholar
• Mukhitdinova O, Alyavi BA, Ubaydullaeva ZZ, et al. Changes of blood D-dimer level after COVID-19 in patients with coronary heart disease. Eur Heart J Acute Cardiovasc Care. 2022;11(Suppl 1):zuac041.136. doi:10.1093/ehjacc/zuac041.136
   Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Lippi G, Lavie CJ, Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis. Prog Cardiovasc Dis. 2020;63(3):390–391. doi:10.1016/j.pcad.2020.03.001
   PubMed Web of Science ®Google Scholar
• Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;27:201017.
   Google Scholar
• Clerkin KJ, Fried JA, Raikhelkar J. COVID-19 and cardiovascular disease. Circulation. 2020;141:1648–1655. doi:10.1161/CIRCULATIONAHA.120.046941
   PubMed Web of Science ®Google Scholar
• Wei ZY, Qian HY. Myocardial injury in patients with COVID-19 pneumonia. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:006.
   PubMedGoogle Scholar
• Garg A, Seeliger B, Derda AA, et al. Circulating cardiovascular microRNAs in critically ill COVID-19 patients. Eur J Heart Fail. 2021;23(3):468–475. doi:10.1002/ejhf.2096
   PubMed Web of Science ®Google Scholar
• Miyashita Y, Yoshida T, Takagi Y, et al. Circulating extracellular vesicle microRNAs associated with adverse reactions, proinflammatory cytokine, and antibody production after COVID-19 vaccination. NPJ Vaccines. 2022;7(1):16. doi:10.1038/s41541-022-00439-3
   PubMed Web of Science ®Google Scholar
• Dingsdag SA, Clay OK, Quintero GA. COVID-19 severity, miR-21 targets, and common human genetic variation. Letter regarding the article ‘Circulating cardiovascular microRNAs in critically ill COVID-19 patients’. Eur J Heart Fail. 2021;23(11):1986–1987. doi:10.1002/ejhf.2317
   PubMed Web of Science ®Google Scholar
• Silva AB, Siqueira S, de Assis Soares WR, et al. Long-COVID and post-COVID health complications: an up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13(4):700. doi:10.3390/v13040700
   PubMed Web of Science ®Google Scholar
• Ortega-Paz L, Capodanno D, Montalescot G, et al. Coronavirus disease 2019-associated thrombosis and coagulopathy: review of the pathophysiological characteristics and implications for antithrombotic management. J Am Heart Assoc. 2021;10(3):019650. doi:10.1161/JAHA.120.019650
   Web of Science ®Google Scholar
• Kotlyarov S, Kotlyarova A. Molecular pharmacology of inflammation resolution in atherosclerosis. Int J Mol Sci. 2022;23:4808. doi:10.3390/ijms23094808
   PubMed Web of Science ®Google Scholar
• Morrison FJ, Su M, Turchin A. COVID-19 outcomes in patients taking cardioprotective medications. PLoS One. 2022;17(10):e0275787. doi:10.1371/journal.pone.0275787
   PubMed Web of Science ®Google Scholar
• Ganjali S, Bianconi V, Penson PE, et al. Commentary: statins, COVID-19, and coronary artery disease: killing two birds with one stone. Metabolism. 2020;113:154375. doi:10.1016/j.metabol.2020.154375
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Mohammadi SM, Heidari Beni F, et al. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis. Arch Med Sci. 2021;17(3):579–595. doi:10.5114/aoms/132950
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Qin JJ, Cheng X, et al. In-hospital use of statins is associated with a reduced risk of mortality among individuals with COVID-19. Cell Metabol. 2020;32(2):176–187. doi:10.1016/j.cmet.2020.06.015
   PubMed Web of Science ®Google Scholar
• Barkas F, Milionis H, Anastasiou G, et al. Statins and PCSK9 inhibitors: what is their role in coronavirus disease 2019? Med Hypotheses. 2021;146:110452. doi:10.1016/j.mehy.2020.110452
   PubMed Web of Science ®Google Scholar
• Vahedian-Azimi A, Mohammadi SM, Banach M, et al. Improved COVID-19 outcomes following statin therapy: an updated systematic review and meta-analysis. Biomed Res Int. 2021;2021:1901772. doi:10.1155/2021/1901772
   PubMed Web of Science ®Google Scholar
• De Spiegeleer A, Bronselaer A, Teo JT, et al. The effect of ARBs, ACEis, and statins on clinical outcomes of COVID-19 infection among nursing home residents. J Am Med Dir Assoc. 2020;21:909–914. doi:10.1016/j.jamda.2020.06.018
   PubMed Web of Science ®Google Scholar
• Mannarino MR, Bianconi V, Cosentini E, et al. Thyroid-stimulating hormone predicts total cholesterol and low-density lipoprotein cholesterol reduction during the acute phase of COVID-19. J Clin Med. 2022;11:3347. doi:10.3390/jcm11123347
   PubMed Web of Science ®Google Scholar
• Kouhpeikar H, Khosaravizade Tabasi H, Khazir Z, et al. Statin use in COVID-19 hospitalized patients and outcomes: a retrospective study. Front Cardiovasc Med. 2022;9:820260. doi:10.3389/fcvm.2022.820260
   PubMedGoogle Scholar
• Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
   PubMed Web of Science ®Google Scholar
• Caputo I, Caroccia B, Frasson I, et al. Angiotensin II promotes SARS-CoV-2 Infection via upregulation of ACE2 in human bronchial cells. Int J Mol Sci. 2022;23(9):5125. doi:10.3390/ijms23095125
   PubMed Web of Science ®Google Scholar
• Cremer S, Pilgram L, Berkowitsch A, et al. LEOSS study group. Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. PLoS One. 2021;16(10):e0258684. doi:10.1371/journal.pone.0258684
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi:10.1161/CIRCRESAHA.120.317134
   PubMed Web of Science ®Google Scholar
• Al-Kuraishy HM, Al-Gareeb AI, Mostafa-Hedeab G, et al. Effects of β-blockers on the sympathetic and cytokines storms in Covid-19. Front Immunol. 2021;12:749291. doi:10.3389/fimmu.2021.749291
   PubMed Web of Science ®Google Scholar
• Alsagaff MY, Mulia EPB. Hypertension and COVID-19: potential use of beta-blockers and a call for randomized evidence. Indian Heart J. 2021;73(6):757–759. doi:10.1016/j.ihj.2021.10.011
   PubMedGoogle Scholar
• Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumathoid arthritis. Circulation. 2002;106:2184–2187. doi:10.1161/01.CIR.0000037521.71373.44
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Fox B, Urba W, et al. Insights from immuno-oncology: the Society for immunotherapy of cancer statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020;8:e000878. doi:10.1136/jitc-2020-000878
   PubMed Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi:10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med. 2020;382:1787–1799. doi:10.1056/NEJMoa2001282
   PubMed Web of Science ®Google Scholar
• Barkas F, Styla CP, Bechlioulis A, et al. Sinus bradycardia associated with remdesivir treatment in COVID-19: a case report and literature review. J Cardiovasc Dev Dis. 2021;8:18. doi:10.3390/jcdd8020018
   PubMed Web of Science ®Google Scholar
• Baigent C, Windecker S, Andreini D, et al. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. Eur Heart J. 2021;43:1059–1103.
   Web of Science ®Google Scholar
• Govil SR, Weidner G, Merritt-Worden T, et al. Socioeconomic status and improvements in lifestyle, coronary risk factors, and quality of life: the multisite cardiac lifestyle intervention program. Am J Public Health. 2009;99:1263–1270. doi:10.2105/AJPH.2007.132852
   PubMed Web of Science ®Google Scholar
• Jankowski P, Kosior DA, Sowa P, et al. Secondary prevention of coronary artery disease in Poland. results from the Polaspire Survey. Cardiol J. 2020;27(5):533–540. doi:10.5603/CJ.a2020.0072
   PubMed Web of Science ®Google Scholar
• Hamer M, Kivimäki M, Gale CR, et al. Lifestyle risk factors, inflammatory mechanisms, and covid-19 hospitalization: a community-based cohort study of 387,109 adults in UK. Brain Behav Immun. 2020;87:184–187. doi:10.1016/j.bbi.2020.05.059
   PubMed Web of Science ®Google Scholar
• Gaudel P, Neupane S, Koivisto AM, et al. Effects of intervention on lifestyle changes among coronary artery disease patients: a 6‐month follow‐up study. Nurs Open. 2022;9:2024–2036. doi:10.1002/nop2.1212
   PubMed Web of Science ®Google Scholar
• Lamberti N, Straudi S, Manfredini R, et al. Don’t stop walking: the in-home rehabilitation program for peripheral artery disease patients during the COVID-19 pandemic. Intern Emerg Med. 2021;16(5):1307–1315. doi:10.1007/s11739-020-02598-4
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J, Bartelink M, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39:763–816. doi:10.1093/eurheartj/ehx095
   PubMed Web of Science ®Google Scholar
• Hageman D, Fokkenrood HJP, van den Houten LNM, et al. Supervised exercise therapy versus home‐based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev. 2018;2018:4.
   Google Scholar
• Panzavolta C, Zalunardo B, Irsara S, et al. Peripheral artery disease, the ‘lost syndrome’ during lockdown for COVID‑19: a report of three cases. Med Int. 2021;1(5):15. doi:10.3892/mi.2021.15
   PubMedGoogle Scholar
• Stabile E, Piccolo R, Franzese M, et al. A cross-sectional study evaluating hospitalization rates for chronic limb threatening ischemia during the COVID-19 outbreak in Campania, Italy. Vasc Med. 2021;26(2):174–179. doi:10.1177/1358863X20977678
   PubMed Web of Science ®Google Scholar
• Smolderen KG, Lee M, Arora T, et al. Peripheral artery disease and COVID-19 outcomes: insights from the Yale DOM-CovX Registry. Curr Probl Cardiol. 2021;47:101007. doi:10.1016/j.cpcardiol.2021.101007
   PubMed Web of Science ®Google Scholar
• Etkin Y, Conway AM, Silpe J, et al. Acute arterial thromboembolism in patients with COVID-19 in the New York City area. Ann Vasc Sur. 2021;70:290–294. doi:10.1016/j.avsg.2020.08.085
   PubMed Web of Science ®Google Scholar
• Indes JE, Koleilat I, Hatch AN, et al. Early experience with arterial thromboembolic complications in patients with COVID-19. J Vasc Surg. 2021;73(2):381–389. doi:10.1016/j.jvs.2020.07.089
   PubMed Web of Science ®Google Scholar
• Rastogi A, Dogra H, Jude EB. COVID-19 and peripheral arterial complications in people with diabetes and hypertension: a systematic review. Diabetes Metab Syndr. 2021;15(5):102204. doi:10.1016/j.dsx.2021.102204
   PubMed Web of Science ®Google Scholar
• Laksono S, Siregar RH, Kusharsamita H. Chronic limb ischemia manifestation in COVID-19 infection: awareness and treatment in primary care. Univ Med. 2021;40(2):163–172. doi:10.18051/UnivMed.2021.v40.166-175
   Web of Science ®Google Scholar
• Goudarzi E, Yousefimoghaddam F, Ramandi A, et al. COVID-19 and peripheral artery thrombosis: a mini review. Curr Probl Cardiol. 2021;2021:100992.
   Google Scholar
• Tran B. Assessment and management of peripheral arterial disease: what every cardiologist should know. Heart. 2021;107(22):1835–1843. doi:10.1136/heartjnl-2019-316164
   PubMed Web of Science ®Google Scholar
• Saenz-Pipao G, Martinez-Aguilar E, Orbe J, et al. The role of circulating biomarkers in peripheral arterial disease. Int J Mol Sci. 2021;22(7):3601. doi:10.3390/ijms22073601
   PubMed Web of Science ®Google Scholar
• Signorelli S, Anzaldi M, Libra M, et al. Plasma levels of inflammatory biomarkers in peripheral arterial disease. Angiology. 2016;67:870–874. doi:10.1177/0003319716633339
   PubMed Web of Science ®Google Scholar
• Eshaq AM, Almofadhli AA, Aljarba NK, et al. Acute limb ischemia as a concomitant manifestation of COVID-19. Cureus. 2022;14(1). doi:10.7759/cureus.21032
   PubMed Web of Science ®Google Scholar
• McCann AB, Jaff MR. Treatment strategies for peripheral artery disease. Expert Opin Pharmacother. 2009;10(10):1571–1586. doi:10.1517/14656560902988502
   PubMed Web of Science ®Google Scholar
• Aursulesei Onofrei V, Ceasovschih A, Marcu DTM, et al. Mortality risk assessment in peripheral arterial disease—the burden of cardiovascular risk factors over the years: a single center’s experience. Diagnostics. 2022;12:2499. doi:10.3390/diagnostics12102499
   Web of Science ®Google Scholar
• Bianconi V, Mannarino MR, Figorilli F, et al. Low brachial artery flow-mediated dilation predicts worse prognosis in hospitalized patients with COVID-19. J Clin Med. 2021;10:5456. doi:10.3390/jcm10225456
   PubMed Web of Science ®Google Scholar
• Ritti-Dias RM, Correia MA, Carvalho JF, et al. Impact of the COVID-19 pandemic on health lifestyle in patients with peripheral artery disease: a cross-sectional study. J Vasc Nurs. 2022;40(1):54–58. doi:10.1016/j.jvn.2022.01.001
   PubMed Web of Science ®Google Scholar
• Anghel R, Adam CA, Marcu DTM, et al. Cardiac rehabilitation in peripheral artery disease in a tertiary center-impact on arterial stiffness and functional status after 6 months. Life. 2022;12(4):601. doi:10.3390/life12040601
   PubMedGoogle Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi:10.1093/eurheartj/ehab484
   PubMed Web of Science ®Google Scholar
• Akinrinmade AO, Obitulata-Ugwu VO, Obijiofor NB, et al. COVID-19 and acute coronary syndrome: a literature review. Cureus. 2022;14(9):e29747. doi:10.7759/cureus.29747
   PubMed Web of Science ®Google Scholar
• Padureanu V, Bogdan M, Subtirelu MS, et al. Perceptions of COVID-19 vaccination among healthcare professionals in Romania. Rev Med Chir Soc. 2020;124(3):454–460.
   Google Scholar
• Ulinici M, Suljič A, Poggianella M, et al. Characterisation of the antibody response in sinopharm (BBIBP-CorV) recipients and COVID-19 Convalescent Sera from the Republic of Moldova. Vaccines. 2023;11:637.
   Web of Science ®Google Scholar
• Zafar U, Zafar H, Ahmed MS, et al. Link between COVID-19 vaccines and myocardial infarction. World J Clin Cases. 2022;10(28):10109–10119. doi:10.12998/wjcc.v10.i28.10109
   PubMed Web of Science ®Google Scholar
• Ho JS, Sia CH, Ngiam JN, et al. A review of COVID-19 vaccination and the reported cardiac manifestations. Singapore Med J. 2021;2021:1.
   Google Scholar
• Jeet Kaur R, Dutta S, Charan J, et al. Cardiovascular adverse events reported from COVID-19 vaccines: a study based on WHO database. Int J Gen Med. 2021;14(3):909–927. doi:10.2147/IJGM.S299531
   PubMedGoogle Scholar
• Baden LR, El Sahly HM, Essink B, et al; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–416. doi:10.1056/NEJMoa2035389
   PubMed Web of Science ®Google Scholar
• Kim YE, Huh K, Park YJ, et al. Association between vaccination and acute myocardial infarction and ischemic stroke after COVID-19 infection. JAMA. 2022;328(9):887–889. doi:10.1001/jama.2022.12992
   PubMed Web of Science ®Google Scholar
• Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19. Nat Med. 2022;28(3):583–590. doi:10.1038/s41591-022-01689-3
   PubMed Web of Science ®Google Scholar
• Botton J, Jabagi MJ, Bertrand M, et al. Risk for myocardial infarction, stroke, and pulmonary embolism following COVID-19 vaccines in adults younger than 75 years in France. Ann Intern Med. 2022;175(9):1250–1257. doi:10.7326/M22-0988
   PubMed Web of Science ®Google Scholar
• Maadarani O, Bitar Z, Elzoueiry M, et al. Myocardial infarction post COVID-19 vaccine - coincidence, Kounis syndrome or other explanation - time will tell. JRSM Open. 2021;12(8):20542704211025259. doi:10.1177/20542704211025259
   Google Scholar
• Balta A, Ceasovschih A, Șorodoc V, et al. Broad electrocardiogram syndromes spectrum: from common emergencies to particular electrical heart disorders. J Pers Med. 2022;12:1754. doi:10.3390/jpm12111754
   PubMed Web of Science ®Google Scholar
• Bilotta C, Perrone G, Adelfio V, et al. COVID-19 vaccine-related thrombosis: a systematic review and exploratory analysis. Front Immunol. 2021;12:729251. doi:10.3389/fimmu.2021.729251
   PubMedGoogle Scholar
• Fazlollahi A, Zahmatyar M, Noori M, et al. Cardiac complications following mRNA COVID-19 vaccines: a systematic review of case reports and case series. Rev Med Virol. 2022;32(4):e2318. doi:10.1002/rmv.2318
   PubMed Web of Science ®Google Scholar
• Satterfield BA, Bhatt DL, Gersh BJ. Cardiac involvement in the long-term implications of COVID-19. Nat Rev Cardiol. 2022;19(5):332–341. doi:10.1038/s41569-021-00631-3
   PubMed Web of Science ®Google Scholar
• Barda N, Dagan N, Ben-Shlomo Y, et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N Engl J Med. 2021;385:1078–1090. doi:10.1056/NEJMoa2110475
   PubMed Web of Science ®Google Scholar
• Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N Engl J Med. 2021;385:2140–2149. doi:10.1056/NEJMoa2109730
   PubMed Web of Science ®Google Scholar
• Oster ME, Shay DK, Su JR, et al. Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to August 2021. JAMA. 2022;327:331–340. doi:10.1001/jama.2021.24110
   PubMed Web of Science ®Google Scholar
• Ling RR, Ramanathan K, Tan FL, et al. Myopericarditis following COVID-19 vaccination and non-COVID-19 vaccination: a systematic review and meta-analysis. Lancet Respir Med. 2022;10:679–688. doi:10.1016/S2213-2600(22)00059-5
   PubMed Web of Science ®Google Scholar
• Chin SE, Bhavsar SM, Corson A, et al. Cardiac complications associated with COVID-19, MIS-C, and mRNA COVID-19 vaccination. Pediatr Cardiol. 2022;43(3):483–488. doi:10.1007/s00246-022-02851-x
   PubMed Web of Science ®Google Scholar
• Marschner CA, Shaw KE, Tijmes FS, et al. Myocarditis following COVID-19 vaccination. Cardiol Clin. 2022;40(3):375–388. doi:10.1016/j.ccl.2022.05.002
   PubMed Web of Science ®Google Scholar
• Li YE, Wang S, Reiter RJ, et al. Clinical cardiovascular emergencies and the cellular basis of COVID-19 vaccination: from dream to reality? Int J Infect Dis. 2022;124:1–10. doi:10.1016/j.ijid.2022.08.026
   PubMed Web of Science ®Google Scholar
• Parsamanesh N, Karami-Zarandi M, Banach M, et al. Effects of statins on myocarditis: a review of underlying molecular mechanisms. Prog Cardiovasc Dis. 2021;67:53–64. doi:10.1016/j.pcad.2021.02.008
   PubMed Web of Science ®Google Scholar
• Hana D, Patel K, Roman S, et al. Clinical cardiovascular adverse events reported post-COVID-19 vaccination: are they a real risk? Curr Probl Cardiol. 2022;47(3):101077. doi:10.1016/j.cpcardiol.2021.101077
   PubMed Web of Science ®Google Scholar
• Liu R, Pan J, Zhang C, et al. Cardiovascular complications of COVID-19 vaccines. Front Cardiovasc Med. 2022;9:840929. doi:10.3389/fcvm.2022.840929
   PubMed Web of Science ®Google Scholar